144 related articles for article (PubMed ID: 27109639)
1. Successful clinical treatment and functional immunological normalization of human MALT1 deficiency following hematopoietic stem cell transplantation.
Rozmus J; McDonald R; Fung SY; Del Bel KL; Roden J; Senger C; Schultz KR; McKinnon ML; Davis J; Turvey SE
Clin Immunol; 2016 Jul; 168():1-5. PubMed ID: 27109639
[TBL] [Abstract][Full Text] [Related]
2. The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-κB signalling.
Klein T; Fung SY; Renner F; Blank MA; Dufour A; Kang S; Bolger-Munro M; Scurll JM; Priatel JJ; Schweigler P; Melkko S; Gold MR; Viner RI; Régnier CH; Turvey SE; Overall CM
Nat Commun; 2015 Nov; 6():8777. PubMed ID: 26525107
[TBL] [Abstract][Full Text] [Related]
3. Combined immunodeficiency due to MALT1 mutations, treated by hematopoietic cell transplantation.
Punwani D; Wang H; Chan AY; Cowan MJ; Mallott J; Sunderam U; Mollenauer M; Srinivasan R; Brenner SE; Mulder A; Claas FH; Weiss A; Puck JM
J Clin Immunol; 2015 Feb; 35(2):135-46. PubMed ID: 25627829
[TBL] [Abstract][Full Text] [Related]
4. The CARD11-BCL10-MALT1 (CBM) signalosome complex: Stepping into the limelight of human primary immunodeficiency.
Turvey SE; Durandy A; Fischer A; Fung SY; Geha RS; Gewies A; Giese T; Greil J; Keller B; McKinnon ML; Neven B; Rozmus J; Ruland J; Snow AL; Stepensky P; Warnatz K
J Allergy Clin Immunol; 2014 Aug; 134(2):276-84. PubMed ID: 25087226
[TBL] [Abstract][Full Text] [Related]
5. The paracaspase MALT1 cleaves the LUBAC subunit HOIL1 during antigen receptor signaling.
Douanne T; Gavard J; Bidère N
J Cell Sci; 2016 May; 129(9):1775-80. PubMed ID: 27006117
[TBL] [Abstract][Full Text] [Related]
6. Mechanistic understanding of the combined immunodeficiency in complete human CARD11 deficiency.
Lu HY; Sharma M; Sharma AA; Lacson A; Szpurko A; Luider J; Dharmani-Khan P; Shameli A; Bell PA; Guilcher GMT; Lewis VA; Vasquez MR; Desai S; McGonigle L; Murguia-Favela L; Wright NAM; Sergi C; Wine E; Overall CM; Suresh S; Turvey SE
J Allergy Clin Immunol; 2021 Dec; 148(6):1559-1574.e13. PubMed ID: 33872653
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathways: targeting MALT1 paracaspase activity in lymphoma.
Fontán L; Melnick A
Clin Cancer Res; 2013 Dec; 19(24):6662-8. PubMed ID: 24004675
[TBL] [Abstract][Full Text] [Related]
8. A20 negatively regulates T cell receptor signaling to NF-kappaB by cleaving Malt1 ubiquitin chains.
Düwel M; Welteke V; Oeckinghaus A; Baens M; Kloo B; Ferch U; Darnay BG; Ruland J; Marynen P; Krappmann D
J Immunol; 2009 Jun; 182(12):7718-28. PubMed ID: 19494296
[TBL] [Abstract][Full Text] [Related]
9. Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.
Ma Y; Liao Z; Xu Y; Zhong Z; Wang X; Zhang F; Chen S; Yang L; Luo G; Huang X; Huang S; Wu X; Li Y
Eur J Med Res; 2014 Nov; 19(1):62. PubMed ID: 25384343
[TBL] [Abstract][Full Text] [Related]
10. Interplay between BCL10, MALT1 and IkappaBalpha during T-cell-receptor-mediated NFkappaB activation.
Carvalho G; Le Guelte A; Demian C; Vazquez A; Gavard J; Bidère N
J Cell Sci; 2010 Jul; 123(Pt 14):2375-80. PubMed ID: 20551178
[TBL] [Abstract][Full Text] [Related]
11. Probes to monitor activity of the paracaspase MALT1.
Hachmann J; Edgington-Mitchell LE; Poreba M; Sanman LE; Drag M; Bogyo M; Salvesen GS
Chem Biol; 2015 Jan; 22(1):139-47. PubMed ID: 25556944
[TBL] [Abstract][Full Text] [Related]
12. The CBM Complex Underwrites NF-κB Activation to Promote HER2-Associated Tumor Malignancy.
Pan D; Zhu Y; Zhou Z; Wang T; You H; Jiang C; Lin X
Mol Cancer Res; 2016 Jan; 14(1):93-102. PubMed ID: 26392569
[TBL] [Abstract][Full Text] [Related]
13. The Paracaspase MALT1.
Hachmann J; Salvesen GS
Biochimie; 2016 Mar; 122():324-38. PubMed ID: 26386283
[TBL] [Abstract][Full Text] [Related]
14. Novel MALT1 Mutation Linked to Immunodeficiency, Immune Dysregulation, and an Abnormal T Cell Receptor Repertoire.
Frizinsky S; Rechavi E; Barel O; Najeeb RH; Greenberger S; Lee YN; Simon AJ; Lev A; Ma CA; Sun G; Blackstone SA; Milner JD; Somech R; Stauber T
J Clin Immunol; 2019 May; 39(4):401-413. PubMed ID: 31037583
[TBL] [Abstract][Full Text] [Related]
15. TRAF2-binding BIR1 domain of c-IAP2/MALT1 fusion protein is essential for activation of NF-kappaB.
Garrison JB; Samuel T; Reed JC
Oncogene; 2009 Apr; 28(13):1584-93. PubMed ID: 19234489
[TBL] [Abstract][Full Text] [Related]
16. Structural determinants of MALT1 protease activity.
Wiesmann C; Leder L; Blank J; Bernardi A; Melkko S; Decock A; D'Arcy A; Villard F; Erbel P; Hughes N; Freuler F; Nikolay R; Alves J; Bornancin F; Renatus M
J Mol Biol; 2012 May; 419(1-2):4-21. PubMed ID: 22366302
[TBL] [Abstract][Full Text] [Related]
17. Uncoupling Malt1 threshold function from paracaspase activity results in destructive autoimmune inflammation.
Gewies A; Gorka O; Bergmann H; Pechloff K; Petermann F; Jeltsch KM; Rudelius M; Kriegsmann M; Weichert W; Horsch M; Beckers J; Wurst W; Heikenwalder M; Korn T; Heissmeyer V; Ruland J
Cell Rep; 2014 Nov; 9(4):1292-305. PubMed ID: 25456129
[TBL] [Abstract][Full Text] [Related]
18. MALT1 cleaves the E3 ubiquitin ligase HOIL-1 in activated T cells, generating a dominant negative inhibitor of LUBAC-induced NF-κB signaling.
Elton L; Carpentier I; Staal J; Driege Y; Haegman M; Beyaert R
FEBS J; 2016 Feb; 283(3):403-12. PubMed ID: 26573773
[TBL] [Abstract][Full Text] [Related]
19. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
Quancard J; Klein T; Fung SY; Renatus M; Hughes N; Israël L; Priatel JJ; Kang S; Blank MA; Viner RI; Blank J; Schlapbach A; Erbel P; Kizhakkedathu J; Villard F; Hersperger R; Turvey SE; Eder J; Bornancin F; Overall CM
Nat Chem Biol; 2019 Mar; 15(3):304-313. PubMed ID: 30692685
[TBL] [Abstract][Full Text] [Related]
20. MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression.
Afonina IS; Elton L; Carpentier I; Beyaert R
FEBS J; 2015 Sep; 282(17):3286-97. PubMed ID: 25996250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
